AU2003289386A1 - Jnk inhibitors - Google Patents
Jnk inhibitorsInfo
- Publication number
- AU2003289386A1 AU2003289386A1 AU2003289386A AU2003289386A AU2003289386A1 AU 2003289386 A1 AU2003289386 A1 AU 2003289386A1 AU 2003289386 A AU2003289386 A AU 2003289386A AU 2003289386 A AU2003289386 A AU 2003289386A AU 2003289386 A1 AU2003289386 A1 AU 2003289386A1
- Authority
- AU
- Australia
- Prior art keywords
- jnk inhibitors
- jnk
- inhibitors
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000012825 JNK inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2002-366257 | 2002-12-18 | ||
| JP2002366257 | 2002-12-18 | ||
| PCT/JP2003/016159 WO2004054979A1 (en) | 2002-12-18 | 2003-12-17 | Jnk inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2003289386A1 true AU2003289386A1 (en) | 2004-07-09 |
Family
ID=32588301
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2003289386A Abandoned AU2003289386A1 (en) | 2002-12-18 | 2003-12-17 | Jnk inhibitors |
Country Status (2)
| Country | Link |
|---|---|
| AU (1) | AU2003289386A1 (en) |
| WO (1) | WO2004054979A1 (en) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005074921A1 (en) * | 2004-02-09 | 2005-08-18 | University Of Zurich | Treatment of atherosclerosis |
| EP1676574A3 (en) | 2004-12-30 | 2006-07-26 | Johnson & Johnson Vision Care, Inc. | Methods for promoting survival of transplanted tissues and cells |
| TWI417095B (en) | 2006-03-15 | 2013-12-01 | Janssen Pharmaceuticals Inc | 1,4-disubstituted 3-cyano-pyridone derivatives and their use as positive allosteric modulators of mglur2-receptors |
| TW200845978A (en) | 2007-03-07 | 2008-12-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives |
| TW200900065A (en) | 2007-03-07 | 2009-01-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives |
| NZ584148A (en) | 2007-09-14 | 2011-05-27 | Ortho Mcneil Janssen Pharm | 1,3-disubstituted-4-phenyl-1 h-pyridin-2-ones |
| MY152078A (en) | 2007-09-14 | 2014-08-15 | Ortho Mcneil Janssen Pharm | 1',3'-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2h,1'h-[1,4']bipyridinyl-2'-ones |
| CA2697399C (en) | 2007-09-14 | 2016-01-19 | Ortho-Mcneil-Janssen Pharmaceuticals, Inc. | 1,3-disubstituted 4-(aryl-x-phenyl)-1h-pyridin-2-ones |
| RU2492170C9 (en) | 2007-11-14 | 2013-12-27 | Орто-Макнейл-Янссен Фармасьютикалз, Инк. | Imidazo[1,2-a]pyridine derivatives and their application as positive allosteric modulators of mglur2 receptors |
| AU2009289784B2 (en) | 2008-09-02 | 2012-03-22 | Addex Pharma S.A. | 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors |
| ES2466341T3 (en) | 2008-10-16 | 2014-06-10 | Janssen Pharmaceuticals, Inc. | Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors |
| WO2010060589A1 (en) | 2008-11-28 | 2010-06-03 | Ortho-Mcneil-Janssen Pharmaceuticals, Inc. | Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors |
| AU2010246609B2 (en) | 2009-05-12 | 2013-09-05 | Addex Pharma S.A. | 1,2,4-triazolo [4,3-a] pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders |
| NZ596053A (en) | 2009-05-12 | 2013-05-31 | Janssen Pharmaceuticals Inc | 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
| MY153913A (en) | 2009-05-12 | 2015-04-15 | Janssen Pharmaceuticals Inc | 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
| CN103298810B (en) | 2010-11-08 | 2016-03-16 | 杨森制药公司 | The purposes of 1,2,4-triazolo [4,3-a] pyridine derivate and the positive allosteric modulators as MGLUR2 acceptor thereof |
| EP2643320B1 (en) | 2010-11-08 | 2015-03-04 | Janssen Pharmaceuticals, Inc. | 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS |
| EP2661435B1 (en) | 2010-11-08 | 2015-08-19 | Janssen Pharmaceuticals, Inc. | 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS |
| JO3368B1 (en) | 2013-06-04 | 2019-03-13 | Janssen Pharmaceutica Nv | 6, 7- dihydropyrazolu [5,1-a] pyrazine-4 (5 hands) -on compounds and their use as negative excretory regulators of Miglore 2 receptors. |
| JO3367B1 (en) | 2013-09-06 | 2019-03-13 | Janssen Pharmaceutica Nv | 1,2,4-TRIAZOLO[4,3-a]PYRIDINE COMPOUNDS AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS |
| DK3096790T3 (en) | 2014-01-21 | 2019-10-07 | Janssen Pharmaceutica Nv | COMBINATIONS INCLUDING POSITIVE ALLOSTERIC MODULATORS OR ORTHOSTERIC AGONISTS OF METABOTROP GLUTAMATERG SUBTYPE 2 RECEPTOR AND APPLICATION OF THESE |
| KR20220038826A (en) | 2014-01-21 | 2022-03-29 | 얀센 파마슈티카 엔.브이. | Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use |
| WO2023086799A1 (en) * | 2021-11-09 | 2023-05-19 | Vigil Neuroscience, Inc. | Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5495580A (en) * | 1978-01-06 | 1979-07-28 | Mitsui Toatsu Chem Inc | Isocarbostyril derivative |
| US4283539A (en) * | 1979-12-18 | 1981-08-11 | Pfizer Inc. | Isoquinoline acetic acids |
| SU1659413A1 (en) * | 1989-03-30 | 1991-06-30 | Киевский Государственный Университет Им.Т.Г.Шевченко | 3-amino-2-benzyl-4-(1-methylbenzumudazole-2-yl)-7-nitro-1(2n) isochinolone as reagent for photometric determination of copper and method for its preparation |
| SU1728242A1 (en) * | 1989-07-18 | 1992-04-23 | Киевский Государственный Университет Им.Т.Г.Шевченко | Method of 3-amino-1(2h)-isoquinolones synthesis |
| EP0424929A1 (en) * | 1989-10-27 | 1991-05-02 | Takeda Chemical Industries, Ltd. | Isoquinolone derivatives, their production and use |
| JP2984403B2 (en) * | 1991-02-21 | 1999-11-29 | 日清製粉株式会社 | Isoquinolone derivative |
| US5877278A (en) * | 1992-09-24 | 1999-03-02 | Chiron Corporation | Synthesis of N-substituted oligomers |
| DE19729061A1 (en) * | 1997-07-08 | 1999-01-14 | Agfa Gevaert Ag | Colour photographic material sensitised without increased fogging |
| US6200976B1 (en) * | 1998-04-17 | 2001-03-13 | Boehringer Ingelheim Pharma Kg | Antithrombotic quinoxazolines |
| EP1091960A1 (en) * | 1998-06-29 | 2001-04-18 | The Regents Of The University Of California | Bifunctional antagonists of cytokine-sensitive protein kinase activation cascades and methods for use as anti-inflammatory agents |
| ES2231158T3 (en) * | 1999-02-12 | 2005-05-16 | Smithkline Beecham Plc | DERIVATIVES AND FENIL UREA AND FIO TIOUREA. |
| IL157179A0 (en) * | 2001-02-02 | 2004-02-08 | Takeda Chemical Industries Ltd | Fused heterocyclic compounds |
| CA2476162A1 (en) * | 2002-02-13 | 2003-08-21 | Takeda Chemical Industries, Ltd. | Jnk inhibitor |
-
2003
- 2003-12-17 WO PCT/JP2003/016159 patent/WO2004054979A1/en not_active Ceased
- 2003-12-17 AU AU2003289386A patent/AU2003289386A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2004054979A1 (en) | 2004-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2003211931A1 (en) | Jnk inhibitor | |
| AU2003202263A1 (en) | Roh-kinase inhibitors | |
| AU2003249442A1 (en) | Kinase inhibitors | |
| AU2003222055A1 (en) | Kinase inhibitors | |
| AU2003239909A1 (en) | Enhanced-service provision | |
| AU2003271566A1 (en) | Pyrrolopyrazines as kinase inhibitors | |
| AU2003289386A1 (en) | Jnk inhibitors | |
| AU2003241030A1 (en) | Opteolectronic devices | |
| AU2002952554A0 (en) | Monitower | |
| AU2003249683A1 (en) | Nf-:b inhibitors | |
| AU2003289287A1 (en) | Jnk inhibitor | |
| AU2003215635A1 (en) | Thiazol-2-yl-imine compounds as pde-7 inhibitors | |
| AU2003244080A1 (en) | Phosphodiesterase inhibitor | |
| AU2003256323A1 (en) | Sos1 inhibitors | |
| AUPS251402A0 (en) | Kinase inhibitors | |
| AU2003264722A1 (en) | Methods | |
| AU2003254900A1 (en) | Bit reduction device | |
| AU2003299126A1 (en) | Two-sail rig | |
| AU2003208685A1 (en) | Podologic aid | |
| AU2002318053A1 (en) | Suplier | |
| AU2003285894A1 (en) | Multiple well device | |
| AU2003212130A1 (en) | Can | |
| AU2002330448A1 (en) | Jnk inhibitors | |
| AU2003260462A1 (en) | Rapid application integration | |
| AU2003215235A1 (en) | Cks1 INHIBITORS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |